Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients | Zendy

Emanuele Focà | Zendy; Andrea Calcagno | Zendy; Andrea Bonito | Zendy; Marco Simiele | Zendy; Elisabetta Domenighini | Zendy; Antonio D’Avolio | Zendy; Eugenia Quirós-Roldán | Zendy; L. Trentini | Zendy; Salvatore Casari | Zendy; Giovanni Di Perri | Zendy; Francesco Castelli | Zendy; Stefano Bonora | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients

Author(s) -

Emanuele Focà,

Andrea Calcagno,

Andrea Bonito,

Marco Simiele,

Elisabetta Domenighini,

Antonio D’Avolio,

Eugenia Quirós-Roldán,

L. Trentini,

Salvatore Casari,

Giovanni Di Perri,

Francesco Castelli,

Stefano Bonora

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx274

Subject(s) - atazanavir , ritonavir , medicine , pharmacology , emtricitabine , pregnancy , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , genetics

Atazanavir (300 mg) boosted by ritonavir (100 mg) is the preferred third drug in pregnancy. However, there is still discordance on atazanavir dose increase during the third trimester.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research